<DOC>
	<DOCNO>NCT00450983</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy total-body irradiation donor peripheral blood stem cell donor natural killer cell transplant help stop growth cancer abnormal cell help stop patient 's immune system reject donor 's stem cell . When certain stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Removing T cell donor cell transplant may stop happen . PURPOSE : This phase II trial study well give donor peripheral stem cell transplant donor natural killer cell transplant total-body irradiation , thiotepa , fludarabine , muromonab-CD3 work treat patient leukemia blood disease .</brief_summary>
	<brief_title>Donor Peripheral Stem Cell Transplant Donor Natural Killer Cell Transplant After Total-Body Irradiation , Thiotepa , Fludarabine , Muromonab-CD3 Treating Patients With Leukemia Other Blood Diseases</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine effect haploidentical donor CD34+ purify peripheral blood stem cell donor natural killer ( NK ) cell risk develop grade III-IV acute graft-vs-host disease patient leukemia hematologic disease . Secondary - Determine risk mortality infection day 180 patient treated regimen . - Determine risk graft rejection patient treat regimen . - Determine risk life-threatening infection patient treat regimen . - Determine concentration subset NK , NK-T , T cell , dendritic cell CD34+ NK/NK-T-enriched graft . - Determine cytomegalovirus-specific T-cells product donor graft . - Determine genotype phenotype donor killer cell immunoglobulin-like receptor expression accord time hematopoietic stem cell transplantation ( HSCT ) . - Determine reconstitution NK function accord time HSCT . - Determine expression NKG2 ligands leukemic blast . OUTLINE : Patients stratify accord age ( ≤ 7 year vs &gt; 7 year ) . - Conditioning regimen : Patients 7 year age young undergo total-body irradiation ( TBI ) twice daily day -11 -9 . Patients 7 year age undergo TBI day -9 . All patient receive thiotepa IV 2 hour day -8 -7 , fludarabine phosphate IV day -6 -3 muromonab-CD3 day -6 6 . Patients acute lymphoblastic leukemia leukemia spinal fluid also receive methotrexate intrathecally prior donor peripheral blood stem cell ( PBSC ) transplantation . - Donor PBSC transplantation : Patients undergo donor PBSC transplantation comprise CD34+ purify PBSCs natural killer ( NK ) cell day 0 . Blood sample collect week 1-4 , 6 , 8 , 12 . Analysis sample include quantitation NK , NK-T , T-cell subset ( CD3 , CD4 , CD8 ) flow cytometry ; donor killer cell immunoglobulin-like receptor genotype phenotype ; interferon-gamma level ; NK cytotoxicity . Samples also analyze leukemic blast assay determine ligand activate NK cell express . After completion study therapy , patient follow periodically . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Muromonab-CD3</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 follow lifethreatening hematological malignancy : Acute lymphoblastic leukemia meeting 1 follow criterion : Advanced beyond first remission In first remission highrisk prognostic feature , include follow : Philadelphia chromosomepositive disease Chromosome 11q23 abnormality Hypodiploid Failed achieve first remission within 1 month induction Acute myeloid leukemia ( AML ) meet 1 follow criterion : Advanced beyond first remission First remission highrisk prognostic feature , include follow : Chromosome 11q23 abnormality Chromosome del 7q Secondary AML Failed achieve first remission within 1 month induction Myelodysplastic syndromes International Prognostic Score &gt; 1 Chronic myelogenous leukemia accelerate blastic phase No active CNS disease No suitable HLAmatched relate unrelated donor available Haploidentical family member available donor partially HLAmatched peripheral blood stem cell Least degree mismatch HLAA , B , C , DRB1 , DQB1 No mismatch single HLAA , B , C , DRB1 , DQB1 antigen Donor killer cell immunoglobulinlike receptor ligand group expression preferably different patient PATIENT CHARACTERISTICS : LVEF ≥ 45 % DLCO ≥ 60 % predict AST ALT ≤ 2 time upper limit normal ( ULN ) ( unless due malignancy ) Bilirubin ≤ 2 time ULN ( unless due malignancy ) No life expectancy &lt; 6 month due coexist disease malignancy No active infection ( e.g. , polymerase chain reaction [ PCR ] evidence cytomegalovirus , human herpes virus 6 , invasive fungal infection ) No prior infection without evidence resolution PCR imaging study within past 2 month No hypersensitivity murine antibodies No known HIV positivity Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : No prior marrow transplantation total body irradiation &gt; 400 cGy No concurrent therapy seizure disorder No growth factor 21 day transplantation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>